Sign In
Buy CLVS
$0.151
+0 (+0%)
At Close: Apr 19, 2023
2 Biotech Stocks That Could Go Parabolic
12:30pm, Monday, 16'th May 2022 The Motley Fool
These gems are hiding in a sector that has been pummeled so far this year.
Viatris' (VTRS) Q1 Earnings Beat, Revenues Miss Estimates
03:09pm, Monday, 09'th May 2022 Zacks Investment Research
Viatris (VTRS) beats on Q1 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.
Alcon (ALC) to Report Q1 Earnings: What's in the Cards?
03:05pm, Monday, 09'th May 2022 Zacks Investment Research
Strength in Vision Care with the addition of new products and recent acquisition is likely to have contributed to Alcon's (ALC) first-quarter performance.
Endo (ENDP) Beats on Q1 Earnings, Guides Weak Q2 Results
05:23pm, Friday, 06'th May 2022 Zacks Investment Research
Endo (ENDP) tops Q1 earnings and sales estimates. However, Vasostrict faces generic competition and the guidance for Q2 is dismal.
STERIS (STE) to Report Q4 Earnings: What's in the Cards?
02:56pm, Friday, 06'th May 2022 Zacks Investment Research
Strength in Healthcare and AST arms is expected to have driven STERIS' (STE) fourth-quarter revenues.
Why Clovis Oncology Stock Was Plummeting This Week
11:12am, Friday, 06'th May 2022 The Motley Fool
Investors bailed from the company after a quarterly results and operational update.
Why Clovis Oncology Stock Was Plummeting This Week
07:12am, Friday, 06'th May 2022
Investors bailed from the company after a quarterly results and operational update.
Global Blood (GBT) Q1 Loss Narrower Than Expected, Revenues Lag
02:22pm, Thursday, 05'th May 2022 Zacks Investment Research
Global Blood Therapeutics (GBT) reports y/y wider loss in Q1. Revenues witness a rise.
Clovis (CLVS) Q1 Loss Wider than Expected, Revenues Miss
06:21pm, Wednesday, 04'th May 2022 Zacks Investment Research
Clovis (CLVS) incurs wider-than-estimated loss for first-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.
Clovis (CLVS) Q1 Loss Wider than Expected, Revenues Miss
03:48pm, Wednesday, 04'th May 2022
Clovis (CLVS) incurs wider-than-estimated loss for first-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.
Clovis Oncology (CLVS) Reports Q1 Loss, Lags Revenue Estimates
01:15pm, Wednesday, 04'th May 2022 Zacks Investment Research
Clovis (CLVS) delivered earnings and revenue surprises of -2.33% and 7.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q1 2022 Results - Earnings Call Transcript
12:30pm, Wednesday, 04'th May 2022
Clovis Oncology, Inc. (NASDAQ:CLVS ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Anna Sussman - VP, IR and Corporate Communications Patrick Mahaffy - President and CEO
Onconova (ONTX) to Report Q1 Earnings: What's in the Cards?
05:00pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Investors will watch for updates on its lead candidate narazaciclib when Onconova Therapeutics. (ONTX) reports first-quarter earnings.
Viatris (VTRS) to Report Q1 Earnings: What's in the Cards?
04:10pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Viatris' (VTRS) Q1 earnings might have been adversely impacted by competition in the complex generics business.
Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates
12:35pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 0% and 45.15%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
